Hemostasis Today

November, 2026
November 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Abdlemewla Ibrahim: Prasugrel vs Ticagrelor in ACS Patients Undergoing PCI
Nov 17, 2026, 13:37

Abdlemewla Ibrahim: Prasugrel vs Ticagrelor in ACS Patients Undergoing PCI

Abdlemewla Ibrahim, Internist, shared a post on LinkedIn about a recent article  by Elmir Omerovic et al., published in The New England Journal of Medicine, adding:

” Switch-Swedehearth (ClinicalTrials.gov NCT05183178) is a large, pragmatic, registry-based, stepped-wedge cluster-randomized trial that compared a default policy of prasugrel versus ticagrelor as the P2Y12 inhibitor (plus aspirin) after PCI in patients with acute coronary syndrome (ACS).​
Nejm

Key design features

  • Conducted within the nationwide Swedish Swedehearth registry.
  • Seven Swedish regions (grouped into three clusters covering roughly half the country’s population) switched their recommended default P2Y12 inhibitor from ticagrelor to prasugrel in a randomly ordered, staggered fashion across four 9-month periods (May 2021–August 2024).
  • Open-label; the final drug choice remained at the treating physician’s discretion.
  • Included an unselected, consecutive real-world population of adults undergoing PCI for ACS (including elderly patients, those with prior stroke, and those with an indication for oral anticoagulation—groups often excluded from traditional trials).
  • Primary endpoint: composite of death from any cause, myocardial infarction, or stroke at 1 year.
  • Secondary endpoint of interest: major bleeding at 1 year.​
  • News-medical

Main results (17,095 patients)

Ticagrelor-policy group: 9,444 patients (recommended ticagrelor 90 mg twice daily).

Prasugrel-policy group: 7,651 patients (recommended prasugrel 10 mg once daily, reduced to 5 mg in those 75 years or older or less than 60 kg).

Mean age approximately 69.8 years; approximately 28 percent women; substantial proportion 75 years or older.

Primary endpoint (death/MI/stroke at 1 year): 11.1 percent (prasugrel policy) vs 11.8 percent (ticagrelor policy); adjusted OR 0.90 (95 percent  CI 0.77–1.06). No significant differences in the individual components (all-cause death, MI, stroke, or stent thrombosis).

Major bleeding at 1 year: lower with the prasugrel policy (4.2 percent vs 4.4 percent; adjusted OR 0.80, 95 percent CI 0.64–0.99).​

Escardio

Conclusions and context

A regional default policy of prasugrel did not reduce ischemic events compared with ticagrelor in this broad, unselected ACS-PCI population, but it was associated with a modest reduction in major bleeding (and is generally lower-cost). The trial provides high-quality pragmatic evidence complementing earlier findings (e.g., ISAR-REACT 5) and illustrates the value of registry-embedded randomized trials for answering real-world policy questions efficiently.​”

Title: Prasugrel versus Ticagrelor in Acute Coronary Syndromes

Authors: Elmir Omerovic, Sasha Koul, Jonas Andersson,  Johan Pontén, Fredrik Björklund,  Robert Kastberg, Mila Sun, Charlotta Ljungman, Ole Fröbert,  Kristian Bolin, Kristofer Skoglund, Carl-David Dolata, Mats Birgander, Helena Wikström, Truls Råmunddal, Oskar Angerås, Petur Petursson, David Erlinge, Björn Redfors

Abdlemewla Ibrahim: Prasugrel vs Ticagrelor in ACS Patients Undergoing PCI

Stay updated with all scientific advances with Hemostasis Today.